Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Nature reviews. Clinical oncology - 1 Aug 2016

Penault-Llorca Frederique, Radosevic-Robin Nina

Abstract excerpt

Nowadays, the decision of which adjuvant treatment should be given to patients with residual breast cancer after neoadjuvant therapy is based on the initial, pretreatment breast cancer molecular subtype and on the estimated residual tumour burden after neoadjuvant therapy. Substantial biological differences exist, however, between treatment-naive breast cancer and the residual tissue that remains after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ki-67 Antigen
Share to Neoadjuvant Therapy
Share to Neoplasm Grading

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Proteome

Share to Receptor, ErbB-2

Share to Tumor Burden

Share to Tumor Microenvironment

Source

Identifiers

PMID: 26856744
DOI: 10.1038/nrclinonc.2016.1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of residual disease after neoadjuvant therapy for breast cancer.PMID 26856744Read ↗

Predictive factors for response to neoadjuvant therapy in breast cancer.Semantic proximity Read ↗

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.Semantic proximity Read ↗

Scoping Review: Emerging (Bio)markers for the Early Detection of Breast Cancer RecurrenceSemantic proximity Read ↗

Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity Read ↗

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.Semantic proximity Read ↗

Decoding the adaptive survival mechanisms of breast cancer dormancySemantic proximity Read ↗

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read ↗

Outcome Prediction after Neoadjuvant Chemotherapy (NAC) for Breast Cancer, using Tumor-Infiltrating Lymphocytes within Fibrotic Foci of Tumor Stroma (FF-TILs)Semantic proximity Read ↗

Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?Semantic proximity Read ↗

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumoursSemantic proximity Read ↗

PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer.Semantic proximity Read ↗

Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.